KS18, a Mcl-1 inhibitor, improves the effectiveness of bortezomib and overcomes resistance in refractory multiple myeloma by triggering intrinsic apoptosis
Despite a record number of clinical studies investigating various anti-myeloma treatments, the 5-year survival rate for multiple myeloma (MM) patients in the US is only 55%, and almost all patients relapse. Poor patient outcomes demonstrate that myeloma cells are “born to survive” which means they c...
Salvato in:
| Autori principali: | , , , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Frontiers Media S.A.
2024-10-01
|
| Serie: | Frontiers in Pharmacology |
| Soggetti: | |
| Accesso online: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1436786/full |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|